Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTH NYSE:ENOV NASDAQ:PLSE NASDAQ:PRCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$11.12-1.1%$9.86$8.12▼$18.23$384.23M0.54423,433 shs75,589 shsENOVEnovis$26.38-3.2%$23.86$21.00▼$37.85$1.51B1.411.01 million shs306,074 shsPLSEPulse Biosciences$19.13-2.3%$20.85$12.56▼$26.30$1.29B1.63309,531 shs39,580 shsPRCTPROCEPT BioRobotics$25.50+0.2%$25.06$19.35▼$66.85$1.45B0.831.52 million shs207,969 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems-0.18%+8.29%+16.24%+19.96%-3.19%ENOVEnovis+9.66%+16.65%+21.24%+20.70%-20.19%PLSEPulse Biosciences+1.98%-7.46%-1.85%-5.59%+17.31%PRCTPROCEPT BioRobotics+2.58%+5.82%+9.70%-11.48%-52.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$11.12-1.1%$9.86$8.12▼$18.23$384.23M0.54423,433 shs75,589 shsENOVEnovis$26.38-3.2%$23.86$21.00▼$37.85$1.51B1.411.01 million shs306,074 shsPLSEPulse Biosciences$19.13-2.3%$20.85$12.56▼$26.30$1.29B1.63309,531 shs39,580 shsPRCTPROCEPT BioRobotics$25.50+0.2%$25.06$19.35▼$66.85$1.45B0.831.52 million shs207,969 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems-0.18%+8.29%+16.24%+19.96%-3.19%ENOVEnovis+9.66%+16.65%+21.24%+20.70%-20.19%PLSEPulse Biosciences+1.98%-7.46%-1.85%-5.59%+17.31%PRCTPROCEPT BioRobotics+2.58%+5.82%+9.70%-11.48%-52.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 2.67Moderate Buy$22.50102.34% UpsideENOVEnovis 2.90Moderate Buy$47.1478.72% UpsidePLSEPulse Biosciences 2.33Hold$30.0056.82% UpsidePRCTPROCEPT BioRobotics 2.43Hold$41.4562.57% UpsideCurrent Analyst Ratings BreakdownLatest DCTH, PRCT, ENOV, and PLSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ENOVEnovis EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.005/8/2026ENOVEnovis Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.004/30/2026PRCTPROCEPT BioRobotics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$28.00 ➝ $35.004/21/2026PLSEPulse Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PRCTPROCEPT BioRobotics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026ENOVEnovis William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/10/2026ENOVEnovis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/18/2026ENOVEnovis Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/6/2026PRCTPROCEPT BioRobotics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$30.003/5/2026PRCTPROCEPT BioRobotics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/4/2026ENOVEnovis Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$85.23M4.50$0.05 per share215.40$3.15 per share3.53ENOVEnovis$2.25B0.68$28.36 per share0.93$26.09 per share1.01PLSEPulse Biosciences$751K1,737.88N/AN/A$1.19 per share16.08PRCTPROCEPT BioRobotics$308.05M4.71N/AN/A$6.11 per share4.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems$2.70M$0.07159.29111.20N/A3.17%2.63%2.39%N/AENOVEnovis-$1.18B-$20.71N/A6.71N/A-52.69%8.74%4.19%N/APLSEPulse Biosciences-$72.78M-$1.10N/AN/AN/AN/A-80.51%-69.14%N/APRCTPROCEPT BioRobotics-$95.57M-$1.82N/AN/AN/A-31.82%-27.70%-20.29%N/ALatest DCTH, PRCT, ENOV, and PLSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026DCTHDelcath Systems-$0.0971-$0.03+$0.0671-$0.03$23.51 million$24.99 million5/7/2026Q1 2026ENOVEnovis$0.82$0.89+$0.07-$0.15$572.02 million$589.15 million5/4/2026Q1 2026PLSEPulse Biosciences-$0.32-$0.27+$0.05-$0.27$0.25 million$0.40 million4/29/2026Q1 2026PRCTPROCEPT BioRobotics-$0.55-$0.56-$0.01-$0.56$80.52 million$83.13 million2/26/2026Q4 2025DCTHDelcath Systems-$0.06-$0.05+$0.01-$0.05$20.35 million$20.73 million2/26/2026Q4 2025ENOVEnovis$0.81$0.95+$0.14-$9.10$584.30 million$575.76 million2/25/2026Q4 2025PRCTPROCEPT BioRobotics-$0.32-$0.53-$0.21-$0.53$93.70 million$76.38 million2/19/2026Q4 2025PLSEPulse Biosciences-$0.32-$0.26+$0.06-$0.26$0.23 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A10.929.98ENOVEnovis0.852.021.04PLSEPulse BiosciencesN/A10.5310.51PRCTPROCEPT BioRobotics0.156.735.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%ENOVEnovis98.45%PLSEPulse Biosciences76.95%PRCTPROCEPT BioRobotics89.46%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems19.36%ENOVEnovis2.90%PLSEPulse Biosciences74.60%PRCTPROCEPT BioRobotics6.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.46 million27.79 millionOptionableENOVEnovis7,80257.54 million55.87 millionOptionablePLSEPulse Biosciences14068.23 million17.33 millionOptionablePRCTPROCEPT BioRobotics43056.92 million53.16 millionOptionableDCTH, PRCT, ENOV, and PLSE HeadlinesRecent News About These CompaniesHow The PROCEPT BioRobotics (PRCT) Investment Story Is Shifting After Q4 Miss And Guidance ResetMay 4, 2026 | finance.yahoo.comPROCEPT BioRobotics (PRCT)’s Growth Narrative Improves Following Aquablation Upgrade and HYDROS LaunchMay 1, 2026 | insidermonkey.comPROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & JuneApril 30, 2026 | globenewswire.comPROCEPT BioRobotics Corp (PRCT) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...April 30, 2026 | finance.yahoo.comPROCEPT BioRobotics (NASDAQ:PRCT) Shares Gap Up - Still a Buy?April 30, 2026 | marketbeat.comPROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPROCEPT BioRobotics (NASDAQ:PRCT) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPSApril 29, 2026 | marketbeat.comPROCEPT BioRobotics Q1 Earnings Call HighlightsApril 29, 2026 | marketbeat.comPROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue EstimatesApril 29, 2026 | zacks.comPROCEPT BioRobotics Corporation (PRCT) Stock Rises on Q1 2026 EarningsApril 29, 2026 | quiverquant.comQPROCEPT BioRobotics Reports First Quarter 2026 Financial ResultsApril 29, 2026 | globenewswire.comPROCEPT BioRobotics Corp (PRCT) Q1 2026 Earnings Report Preview: What To Look ForApril 28, 2026 | finance.yahoo.com59,200 Shares in PROCEPT BioRobotics Corporation $PRCT Bought by B. Metzler seel. Sohn & Co. AGApril 26, 2026 | marketbeat.comPROCEPT BioRobotics (NASDAQ:PRCT) Rating Increased to Sell at Wall Street ZenApril 25, 2026 | marketbeat.comChicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in StockApril 24, 2026 | fool.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Consensus Recommendation of "Hold" from BrokeragesApril 23, 2026 | marketbeat.comSecurities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...April 22, 2026 | tmcnet.comPROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationApril 22, 2026 | tmcnet.comSecurities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmApril 22, 2026 | businesswire.comPROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationApril 22, 2026 | businesswire.comSecurities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzApril 22, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCTH, PRCT, ENOV, and PLSE Company DescriptionsDelcath Systems NASDAQ:DCTH$11.12 -0.12 (-1.07%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Enovis NYSE:ENOV$26.38 -0.87 (-3.20%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Pulse Biosciences NASDAQ:PLSE$19.13 -0.46 (-2.35%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.PROCEPT BioRobotics NASDAQ:PRCT$25.50 +0.06 (+0.23%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
